Biomedical Science Letters (대한의생명과학회지)

The Korean Society for Biomedical Laboratory Sciences (대한의생명과학회)
권호 표지
DOI QR코드

DOI QR Code

Comparative Proteome Analysis of Celastrol-Treated Helicobacter pylori

  • Kim, Sa-Hyun (Department of Clinical Laboratory Science, Semyung University)
  • Received : 2017.12.05
  • Accepted : 2017.12.18
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Various preclinical and clinical trials have been conducted the efficacy of celastrol. In data presented in the current manuscript is the first trial to inhibit Helicobacter pylori with celastrol. In this study, the quantitative change of various H. pylori proteins including CagA and VacA by the anti-bacterial effect of celastrol was determined. The anti-H. pylori effects of celastrol was investigated by performing 2-dimensional electrophoresis and additional supporting experiments. After 2-dimensional electrophoresis analysis, spot intensities were analyzed and then each spot was identified using matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) or peptide sequencing using Finnigan LCQ ion trap mass spectrometer (LC-MS/MS). The results show that celastrol has multiple effects on protein expression in H. pylori.

Keywords

References

  1. Alm RA, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori. Nature. 1999. 14: 176-180.
  2. Backert S, Kwok T, Schmid M, Selbach M, Moese S, Peek RM Jr, Konig W, Meyer TF, Jungblut PR. Subproteomes of soluble and structure-bound Helicobacter pylori proteins analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proteomics. 2005. 5: 1331-1345. https://doi.org/10.1002/pmic.200401019
  3. Cascao R, Fonseca JE, Moita LF. Celastrol: a spectrum of treatment opportunities in chronic diseases. Frontiers of Medicine. 2017. 15: 69.
  4. Censini S, Lang C, Crabtree JE, Ghiara P, Borodovsky M, Rappuoli R, Covacci A. cag pathogenicity island of Helicobacter pylori encodes type I-specific and disease-associated virulence factors. Proceedings of the National Academy of Sciences of the United States of America. 1996. 93: 14648-14653. https://doi.org/10.1073/pnas.93.25.14648
  5. Cover TL, Cao P, Lind CD, Tham KT, Blaser MJ. Correlation between vacuolating cytotoxin production by Helicobacter pylori isolates in vitro and in vivo. Infection and Immunity. 1993. 61: 5008-5012.
  6. Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nature Reviews of Microbiology. 2005. 3: 320-332. https://doi.org/10.1038/nrmicro1095
  7. Gonzalez L, Marrero K, Reyes O, Rodriguez E, Martinez L, Rodriguez BL. Cloning and expression of a recombinant CagA-gene fragment of Helicobacter pylori and its preliminary evaluation in serodiagnosis. Biomedica. 2013. 33: 546-553.
  8. Guo J, Huang X, Wang H, Yang H. Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cells. PLOS One. 2015. 10: e0140745. https://doi.org/10.1371/journal.pone.0140745
  9. Jungblut PR, Bumann D, Haas G, Zimmy-Arndt U, Holland P, Lamer S, Siejak F, Aebischer A, Meyer TF. Comparative proteome analysis of Helicobacter pylori. Molecular Microbiology. 2000. 36: 710-725.
  10. Kim SH, Kim JB. Comparative proteome analysis of cyanidine 3-O glucoside treated Helicobacter pylori. Biomedical Science Letters. 2015. 21: 233-240. https://doi.org/10.15616/BSL.2015.21.4.233
  11. Lee YY, Belas R. Loss of FliL alters Proteus mirabilis surface sensing and temperature-dependent swarming. Journal of Bacteriology. 2015. 197: 159-173. https://doi.org/10.1128/JB.02235-14
  12. Lee YY, Patellis J, Belas R. Activity of Proteus mirabilis FliL is viscosity dependent and requires extragenic DNA. Journal of Bacteriology. 2013. 195: 823-832. https://doi.org/10.1128/JB.02024-12
  13. Lin L, Sun Y, Wang D, Zheng S, Zhang J, Zheng C. Celastrol ameliorates ulcerative colitis-related colorectal cancer in mice via suppressing inflammatory responses and epithelialmesenchymal transition. Frontiers in Pharmacology. 2016. 13: 320.
  14. Park JW, Song JY, Lee SG, Jun JS, Park JU, Chung MJ, Ju JS, Nizamutdinov D, Chang MW, Youn HS, Kang HL, Baik SC, Lee WK, Cho MJ, Rhee KH. Quantitative analysis of representative proteome components and clustering of Helicobacter pylori clinical strains. Helicobacter. 2006. 11: 533-543. https://doi.org/10.1111/j.1523-5378.2006.00456.x
  15. Shaffer CL, Gaddy JA, Loh JT, Johnson EM, Hill S, Hennig EE, McClain MS, McDonald WH, Cover TL. Helicobacter pylori exploits a unique repertoire of type IV secretion system components for pilus assembly at the bacteria-host cell interface. PLOS Pathogen. 2011. 7: e1002237. https://doi.org/10.1371/journal.ppat.1002237
  16. Shrivastava S, Jeengar MK, Reddy VS, Reddy GB, Naidu VG. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways. Experimental and Molecular Pathology. 2015. 98: 313-327. https://doi.org/10.1016/j.yexmp.2015.03.031
  17. Tomb JF, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD, Ketchum KA, Klenk HP, Gill S, Dougherty BA, Nelson K, Quackenbush J, Zhou L, Kirkness EF, Peterson S, Loftus B, Richardson D, Dodson R, Khalak HG, Glodek A, McKenney K, Fitzegerald LM, Lee N, Adams MD, Hickey EK, Berg DE, Gocayne JD, Utterback TR, Peterson JD, Kelley JM, Cotton MD, Weidman JM, Fujii C, Bowman C, Watthey L, Wallin E, Hayes WS, Borodovsky M, Karp PD, Smith HO, Fraser CM, Venter JC. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature. 1997. 7: 539-547.